Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRFS19
|
|||
| Drug Name |
JNJ-79635322
|
|||
| Synonyms |
JNJ-5322
Click to Show/Hide
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05652335) Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.